Literature DB >> 10733194

Neurotologic follow-up after radiation of posterior fossa tumors.

C Jackson1, K J Doyle, J Shohet, J Robinson.   

Abstract

OBJECTIVE: Stereotactic radiation treatment, also known as gamma knife surgery or radiosurgery, has come into acceptance as a treatment alternative to surgical removal for posterior fossa tumors. The purpose of this article is to describe the role of the neurotologist in the optimal management of neurotologic complications after stereotactic radiation, as illustrated by five patients. STUDY
DESIGN: Retrospective chart review. PATIENTS: Five patients who underwent stereotactic radiation of posterior fossa tumors. MAIN OUTCOME MEASURES: Presence or absence of neurotologic complications (tumor growth, hearing loss, imbalance/ataxia, vertigo, and facial paralysis) or neurosurgical complaints (facial numbness, motor weakness, headache, hydrocephalus, and subarachnoid cysts).
RESULTS: Postradiation neurotologic complaints included vertigo, imbalance/ataxia, and progressive hearing loss in four of the five patients. Continued tumor growth occurred in two patients; two patients had no growth; in one patient the tumor became smaller. The complications of facial nerve paralysis, facial numbness, motor weakness, headache, hydrocephalus, cerebellar edema, and posterior fossa arachnoid cyst formation occurred less frequently.
CONCLUSIONS: Stereotactic radiation of posterior fossa tumors can produce significant neurotologic problems. It is imperative that neurotologists remain involved in the follow-up care of patients with posterior fossa tumors to offer optimal treatment alternatives for the neurotologic disorders.

Entities:  

Mesh:

Year:  2000        PMID: 10733194     DOI: 10.1016/s0196-0709(00)80019-8

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  1 in total

1.  Radiation induces progenitor cell death, microglia activation, and blood-brain barrier damage in the juvenile rat cerebellum.

Authors:  Kai Zhou; Martina Boström; C Joakim Ek; Tao Li; Cuicui Xie; Yiran Xu; Yanyan Sun; Klas Blomgren; Changlian Zhu
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.